Avapritinib Patent Expiration
Avapritinib is Used for treating advanced systemic mastocytosis, including aggressive types, and unresectable or metastatic gastrointestinal stromal tumors with a specific mutation. It was first introduced by Blueprint Medicines Corp
Avapritinib Patents
Given below is the list of patents protecting Avapritinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ayvakit | US12060354 | Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making | Mar 08, 2042 | Blueprint Medicines |
| Ayvakit | US11964980 | Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making | Apr 10, 2040 | Blueprint Medicines |
| Ayvakit | US11999744 | Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making | Apr 10, 2040 | Blueprint Medicines |
| Ayvakit | US12252494 | Dosing regimens of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine for treatment of indolent systemic mastocytosis | Apr 10, 2040 | Blueprint Medicines |
| Ayvakit | US11827642 | Compositions useful for treating disorders related to KIT | Oct 15, 2034 | Blueprint Medicines |
| Ayvakit | US9200002 | Compositions useful for treating disorders related to KIT | Oct 15, 2034 | Blueprint Medicines |
| Ayvakit | US9944651 | Compositions useful for treating disorders related to kit | Oct 15, 2034 | Blueprint Medicines |
| Ayvakit | US9994575 | Compositions useful for treating disorders related to kit | Oct 15, 2034 | Blueprint Medicines |
Avapritinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Avapritinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors | M.D. Anderson Cancer Center | NA |
RECRUITING
(Jun 1, 2026)
| PHASE2 |
| (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis | Cogent Biosciences, Inc. | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE2 |
| (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis | Blueprint Medicines Corporation | NA |
COMPLETED
(Apr 1, 2026)
| PHASE2 |